Invesco Ltd. Has $1.37 Billion Holdings in Elevance Health, Inc. $ELV

Invesco Ltd. lifted its position in Elevance Health, Inc. (NYSE:ELV) by 50.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,903,878 shares of the company’s stock after acquiring an additional 1,306,390 shares during the period. Invesco Ltd.’s holdings in Elevance Health were worth $1,368,505,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Elevance Health in the fourth quarter valued at about $5,941,000. Victory Capital Management Inc. boosted its holdings in shares of Elevance Health by 31.1% during the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after buying an additional 109,462 shares during the period. Bright Rock Capital Management LLC bought a new stake in shares of Elevance Health during the 4th quarter worth about $7,362,000. Prana Capital Management LP grew its stake in Elevance Health by 798.9% in the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock valued at $16,684,000 after buying an additional 45,889 shares during the last quarter. Finally, Loews Corp raised its holdings in Elevance Health by 107.5% in the 3rd quarter. Loews Corp now owns 110,000 shares of the company’s stock valued at $35,543,000 after acquiring an additional 57,000 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.34% of the company’s stock.

Elevance Health Stock Performance

Shares of NYSE:ELV opened at $388.77 on Friday. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $426.98. The company’s 50 day moving average price is $373.89 and its two-hundred day moving average price is $346.61. The firm has a market cap of $84.43 billion, a PE ratio of 16.54, a PEG ratio of 2.21 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts predict that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio is presently 29.26%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Mizuho increased their target price on Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Truist Financial lifted their price target on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a report on Monday, June 1st. JPMorgan Chase & Co. boosted their price target on Elevance Health from $411.00 to $476.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Finally, Robert W. Baird upped their price objective on Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $416.11.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.